Allarity Therapeutics Inc (ALLR) - Total Liabilities
Based on the latest financial reports, Allarity Therapeutics Inc (ALLR) has total liabilities worth $8.43 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Allarity Therapeutics Inc - Total Liabilities Trend (2013–2025)
This chart illustrates how Allarity Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Allarity Therapeutics Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Allarity Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Allarity Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Only World Group Holdings Bhd
KLSE:5260
|
Malaysia | RM195.92 Million |
|
Oncoinvent ASA
OL:ONCIN
|
Norway | Nkr58.63 Million |
|
Paru Co. Ltd
KQ:043200
|
Korea | ₩33.70 Billion |
|
Wescoal Holdings Ltd
JSE:SLG
|
South Africa | ZAC4.45 Billion |
|
Sala @ Sathorn Property Fund
BK:SSPF
|
Thailand | ฿19.90 Million |
|
Central Motek Co Ltd
KO:308170
|
Korea | ₩265.69 Billion |
|
Eagon Ind
KO:008250
|
Korea | ₩211.26 Billion |
|
Mene Inc
V:MENE
|
Canada | CA$2.41 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Allarity Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Allarity Therapeutics Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Allarity Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Allarity Therapeutics Inc (2013–2025)
The table below shows the annual total liabilities of Allarity Therapeutics Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $8.43 Million | -22.23% |
| 2024-12-31 | $10.84 Million | -25.83% |
| 2023-12-31 | $14.61 Million | +15.48% |
| 2022-12-31 | $12.65 Million | -58.98% |
| 2021-12-31 | $30.85 Million | +370.83% |
| 2020-12-31 | $6.55 Million | -38.79% |
| 2019-12-31 | $10.70 Million | +0.17% |
| 2018-12-31 | $10.69 Million | +529.09% |
| 2017-12-31 | $1.70 Million | +27.11% |
| 2016-12-31 | $1.34 Million | +157.91% |
| 2015-12-31 | $518.15K | +3489.03% |
| 2014-12-31 | $14.44K | +15.01% |
| 2013-12-31 | $12.55K | -- |
About Allarity Therapeutics Inc
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead d… Read more